For the third quarter of the fiscal year ending March 2026, revenue amounted to JPY 1,533.5 billion (12.1% YoY increase), core operating income was JPY 249.2 billion (8.8% YoY increase), operating income was JPY 233.8 billion (5.9% YoY decrease), and net income attributable to owners of the parent for the quarter was JPY 217.4 billion (4.2% YoY increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4568","jir_company_name":"Daiichi Sankyo Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4568-20260130-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, revenue amounted to JPY 1,533.5 billion (12.1% YoY increase), core operating income was JPY 249.2 billion (8.8% YoY increase), operating income was JPY 233.8 billion (5.9% YoY decrease), and net income attributable to owners of the parent for the quarter was JPY 217.4 billion (4.2% YoY increase).","jir_summary":"### Performance Overview\nFor the cumulative third quarter period of the fiscal year ending March 2026, revenue increased 12.1% YoY to JPY 1,533.5 billion, supported by strong sales growth of key products Enhertu and Dato-Dowey. Core operating income rose 8.8% to JPY 249.2 billion, securing profit growth; however, operating income declined 5.9% to JPY 233.8 billion due to one-time revenue declines and loss compensation recorded for contract manufacturers. Net income attributable to owners of the parent for the quarter rose 4.2% to JPY 217.4 billion, reflecting reduced corporate tax expenses.\n\n### Segment Performance and Research & Development Status\nThe Japan Business Unit recorded revenue of JPY 390.8 billion, up 1.3% YoY; Daiichi Sankyo Healthcare Unit grew 4.7% to JPY 70.6 billion; Oncology Business Unit increased 30.3% to JPY 439.2 billion; ASCA Business Unit rose 20.8% to JPY 187.2 billion. R&D expenses increased 12.7% to JPY 338.7 billion, with enhanced investments particularly in 5DXd ADCs (such as Enhertu and Dato-Dowey). Multiple clinical trials are underway, progress includes FDA Breakthrough Therapy designations and regulatory filings and approvals in various countries.\n\n### Financial Position and Shareholder Returns\nTotal assets stood at JPY 3,821.8 billion, total liabilities at JPY 2,111.3 billion, and total equity at JPY 1,710.5 billion, resulting in an equity ratio attributable to owners of the parent of 44.8%, a decline from the previous fiscal year-end. Shareholder returns included a forecast annual dividend for fiscal 2025 of JPY 78 (an increase of JPY 18 YoY) and an interim dividend of JPY 39. The company is actively conducting share buybacks, establishing a repurchase program from April 2025 to March 2026 with a ceiling of JPY 200 billion or 80 million shares.","jir_financial_highlights":"Revenue: 1,533,459 million JPY (12.1% YoY increase)\nCore Operating Income: 249,196 million JPY (8.8% YoY increase)\nOperating Income: 233,775 million JPY (5.9% YoY decrease)\nQuarterly Profit Before Tax: 269,950 million JPY (1.8% YoY decrease)\nNet Income Attributable to Owners of Parent: 217,446 million JPY (4.2% YoY increase)\nTotal Assets: 3,821,811 million JPY (Increase from previous fiscal year-end)\nTotal Equity: 1,710,549 million JPY (Increase from previous fiscal year-end)\nEquity Ratio Attributable to Owners of Parent: 44.8% (2.2% decrease from previous fiscal year-end)\nOutstanding Shares (Including Treasury Stock): 1,894,350,529 shares (Decrease from previous fiscal year-end)\nTreasury Stock: 43,292,642 shares (Increase from previous fiscal year-end)\nFull-year Dividend (Forecast): JPY 78 (Dividend increase YoY)","jir_category":"","jir_hashtags":"#DaiichiSankyo, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: 1,533,459 million JPY (12.1% YoY increase)\nCore Operating Income: 249,196 million JPY (8.8% YoY increase)\nNet Income Attributable to Owners of Parent: 217,446 million JPY (4.2% YoY increase)","jir_meta_title":"Daiichi Sankyo Financial Summary for Q3 Fiscal 2026: Revenue Up 12.1%, Quarterly Profit Up 4.2%","jir_meta_description":"Daiichi Sankyo Company, Limited\u2019s financial summary for the third quarter of fiscal year ending March 2026. Revenue reached JPY 1,533.5 billion (12.1% YoY increase), core operating income was JPY 249.2 billion (8.8% YoY increase), and net income attributable to owners of parent was JPY 217.4 billion (4.2% YoY increase). Features increased R&D expenses and shareholder return initiatives.","jir_og_title":"Daiichi Sankyo Q3 Fiscal 2026 Financial Summary: Revenue Up 12.1%, Profits Remain Solid","jir_og_description":"Daiichi Sankyo\u2019s financial summary for the third quarter of fiscal 2026 reports revenue of JPY 1,533.5 billion and quarterly profit of JPY 217.4 billion, achieving growth in both sales and profits.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1367567,1533459],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[248311,233775],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Core Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income\\\",\\\"data\\\":[229009,249196],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit\\\",\\\"data\\\":[208603,217446],\\\"backgroundColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Composition by Business Unit for Cumulative Q3 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan Business Unit\\\",\\\"Daiichi Sankyo Healthcare Unit\\\",\\\"Oncology Business Unit\\\",\\\"American Regent Unit\\\",\\\"EU Specialty Business Unit\\\",\\\"ASCA Business Unit\\\"],\\\"datasets\\\":[{\\\"data\\\":[3908,706,4392,1419,2001,1872],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\",\\\"#59a14f\\\",\\\"#edc948\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"research_development_expense_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Research and Development Expenses Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[300550,338678],\\\"backgroundColor\\\":\\\"#b07aa1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-22163","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n